
Cabaletta Bio Inc is a biotechnology business based in the US. Cabaletta Bio shares (CABA) are listed on the NASDAQ and all prices are listed in US Dollars. Cabaletta Bio employs 56 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Cabaletta Bio
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CABA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Active traders

Cabaletta Bio stock price (NASDAQ: CABA)
Use our graph to track the performance of CABA stocks over time.Cabaletta Bio shares at a glance
Latest market close | $1.15 |
---|---|
52-week range | $0.90 - $14.95 |
50-day moving average | $1.29 |
200-day moving average | $5.34 |
Wall St. target price | $12.50 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.84 |
Buy Cabaletta Bio shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Cabaletta Bio stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Cabaletta Bio price performance over time
Historical closes compared with the close of $1.15 from 2022-07-05
1 week (2022-06-29) | 10.05% |
---|---|
1 month (2022-06-02) | -8.00% |
3 months (2022-04-05) | -44.71% |
6 months (2022-01-05) | -69.66% |
1 year (2021-07-06) | -85.63% |
---|---|
2 years (2020-07-06) | -89.87% |
3 years (2019-07-02) | N/A |
5 years (2017-07-02) | N/A |
Cabaletta Bio financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -28.06% |
Return on equity TTM | -47.17% |
Profit margin | 0% |
Book value | $3.68 |
Market capitalisation | $30.7 million |
TTM: trailing 12 months
Cabaletta Bio share dividends
We're not expecting Cabaletta Bio to pay a dividend over the next 12 months.
Cabaletta Bio share price volatility
Over the last 12 months, Cabaletta Bio's shares have ranged in value from as little as $0.9 up to $14.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cabaletta Bio's is 1.5299. This would suggest that Cabaletta Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cabaletta Bio overview
Cabaletta Bio, Inc. , a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc.
Cabaletta Bio in the news
What Makes Cabaletta Bio, Inc. (CABA) a New Buy Stock
Frequently asked questions
What percentage of Cabaletta Bio is owned by insiders or institutions?Currently 4.314% of Cabaletta Bio shares are held by insiders and 63.978% by institutions. How many people work for Cabaletta Bio?
Latest data suggests 56 work at Cabaletta Bio. When does the fiscal year end for Cabaletta Bio?
Cabaletta Bio's fiscal year ends in December. Where is Cabaletta Bio based?
Cabaletta Bio's address is: 2929 Arch Street, Philadelphia, PA, United States, 19104 What is Cabaletta Bio's ISIN number?
Cabaletta Bio's international securities identification number is: US12674W1099 What is Cabaletta Bio's CUSIP number?
Cabaletta Bio's Committee on Uniform Securities Identification Procedures number is: 12674W109
More guides on Finder
-
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
-
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
-
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert